세계의 의약품 제조 장비 시장 예측(-2029년) : 최종 제품 유형별, 장비 유형별, 지역별

The global pharmaceutical manufacturing equipment market size is projected to grow from USD 19.41 billion in 2024 to USD 26.94 billion in 2029, recording a CAGR of 6.8% during the forecast period. Rising demand for generic drugs is driving the growth of the pharmaceutical manufacturing equipment market. Whereas the demand for refurbished equipments is restraining the growth of the pharmaceutical manufacturing equipment market.

"Packaging machines segment is expected to witness highest CAGR during the forecasted period in pharmaceutical manufacturing equipment market."

The packaging machines segment is expected to have the highest CAGR in the pharmaceutical manufacturing equipment market due to a few critical factors. Innovative drug delivery formats such as pre-filled syringes, single-dose vials, and blister packs are gaining much importance in the pharmaceutical industry, which requires advanced and sophisticated packaging solutions. In addition, adoption of sophisticated packaging technologies, such as serialization and tamper-evident solutions, is stringent regulatory requirements for drug safety and traceability. It is also due to the growing trend of patient-centric healthcare, where packaging is playing an important role in enhancing user convenience and compliance. The growth in biologics, personalized medicines, and vaccines also requires highly precise and sterile packaging environments, thereby further driving demand for advanced packaging machines.

"Liquid segment is likely to witness highest CAGR in pharmaceutical manufacturing equipment market during forecasted period ."

The liquid segment is witnessing the CAGR due to regulatory emphasis on pediatric formulations. Regulatory bodies such as the US Food and Drug Administration (FDA) have stressed the need for age-appropriate liquid medications to address the challenges children face with swallowing solid forms like tablets and capsules. This push ensures better compliance, safety, and efficacy in pediatric treatments, significantly driving demand for liquid dosage forms. Additionally, liquid medications allow precise dosing, making them ideal for children and other patients requiring tailored administration. The growing focus on pediatric health has led pharmaceutical companies to innovate in liquid formulations, opening new market opportunities.

"Europe is expected to hold the second largest market share of the pharmaceutical manufacturing equipment market during forecasted period".

The region is marked by a very competitive landscape, dominated by both large pharmaceutical companies and SMEs, thus facilitating innovation and diversification in terms of products. A tremendous investment in R&D for new manufacturing technologies supports the region's dominance in this market. Biopharmaceuticals form a great shift in the industry and have transformed it across Europe; Germany has emerged to be the largest producer of EU-approved biopharmaceutical substances. This growth is matched by increasing revenues from biologics, which further strengthens the the pharmaceutical manufacturing equipment market in Europe.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Company Type - Tier 1 - 40%, Tier 2 - 35%, Tier 3 - 25%
• By Designation- C-level Executives - 45%, Directors - 35%, Others - 20%
• By Region-North America - 30%, Europe - 25%, Asia Pacific - 40%, RoW - 5%

The pharmaceutical manufacturing equipment market is dominated by a few globally established players such as GEA Group Aktiengesellschaft (Germany), I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A. (Italy), Syntegon Technology GmbH (Germany), Romaco Group (Germany), ACG (India), Korber AG (Germany), Thermo Fisher Scientific Inc. (US), Marchesini Group (Italy), MG2 s.r.l (Italy), Glatt GmbH (Germany). The study includes an in-depth competitive analysis of these key players in the pharmaceutical manufacturing equipment market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

The report segments the pharmaceutical manufacturing equipment and forecasts its size by equipment type, end product type, and region. The report also discusses the drivers, restraints, opportunities, and challenges pertaining to the market. It gives a detailed view of the market across four main regions-North America, Europe, Asia Pacific, and RoW. Supply chain analysis has been included in the report, along with the key players and their competitive analysis in the pharmaceutical manufacturing equipment ecosystem.

Key Benefits to Buy the Report:

• Analysis of key drivers (Rising demand for pharmaceuticals, technological advancements in equipment and growing implementation & adoption of regulatory guidelines). Restraint (Demand for refurbished equipment), Opportunity (Growth in personalized medicines), Challenges (Rising costs and expenditures related to usage of pharmaceutical manufacturing equipment).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the pharmaceutical manufacturing equipment market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the pharmaceutical manufacturing equipment market across varied regions
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the pharmaceutical manufacturing equipment market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players GEA Group Aktiengesellschaft (Germany), I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A. (Italy), Syntegon Technology GmbH (Germany), Romaco Group (Germany), ACG (India) among others in the pharmaceutical manufacturing equipment market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 UNIT CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 LIMITATIONS
• 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 List of primary interview participants
    • 2.1.2.2 Breakdown of primaries
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
  • 2.1.3 SECONDARY AND PRIMARY RESEARCH
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach to arrive at market size through bottom-up analysis (demand side)
  • 2.2.2 TOP-DOWN APPROACH
    • 2.2.2.1 Approach to arrive at market size through top-down analysis (supply side)
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE GROWTH OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET
• 4.2 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY EQUIPMENT TYPE
• 4.3 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY END-PRODUCT TYPE
• 4.4 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing rate of chronic diseases
    • 5.2.1.2 Adoption of modular manufacturing setups
    • 5.2.1.3 Increasing implementation and adoption of regulatory guidelines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Rising adoption of refurbished equipment
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for personalized medicines
    • 5.2.3.2 Rising demand for biopharmaceuticals
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Adherence to multiple regulations and standards
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE PRICING OF KEY PLAYERS, BY EQUIPMENT TYPE, 2023
  • 5.4.2 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL PACKAGING MACHINES, 2019-2023
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION, 2019-2023
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Digital twin
    • 5.8.1.2 Automation and robotics
    • 5.8.1.3 IoT
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 3D printing
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 CAD and CAM
• 5.9 PATENT ANALYSIS
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA (HS CODE 842230)
  • 5.10.2 EXPORT DATA (HS CODE 842230)
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 CASE STUDIES
  • 5.12.1 ZAMBON COMPANY S.P.A. AND IMA ACTIVE COLLABORATED ON PROCESS OPTIMIZATION PROJECT TO ENHANCE BATCH CONSISTENCY AND QUALITY
  • 5.12.2 ACG HELPED INDIAN PHARMACEUTICAL COMPANY RETROFIT B MAX MACHINE WITH NITROGEN-ENHANCED PURGING SYSTEM
  • 5.12.3 SYNTEGON PROVIDED JIANGSU WITH AIM 5022S PLATFORM TO ENHANCE INSPECTION EFFICIENCY AND ACCURACY
• 5.13 REGULATIONS LANDSCAPE
  • 5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13.2 STANDARDS
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 BARGAINING POWER OF SUPPLIERS
  • 5.14.2 BARGAINING POWER OF BUYERS
  • 5.14.3 THREAT OF NEW ENTRANTS
  • 5.14.4 THREAT OF SUBSTITUTES
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA

6 PHARMACEUTICAL MANUFACTURING EQUIPMENT SUPPLIERS AND AFTERMARKET SUPPLIERS

• 6.1 INTRODUCTION
• 6.2 ORIGINAL EQUIPMENT MANUFACTURERS
• 6.3 AFTERMARKET SUPPLIERS

7 MAJOR PHARMACEUTICAL EQUIPMENT MANUFACTURING PROCESSES

• 7.1 INTRODUCTION
• 7.2 FORMULATION PROCESS
• 7.3 TABLETING AND ENCAPSULATION PROCESS
• 7.4 ASEPTIC PROCESS
• 7.5 PACKAGING PROCESS
• 7.6 QUALITY CONTROL PROCESS

8 END USERS OF PHARMACEUTICAL MANUFACTURING EQUIPMENT

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL MANUFACTURING COMPANIES
• 8.3 CONTRACT MANUFACTURING ORGANIZATIONS

9 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY END-PRODUCT TYPE

• 9.1 INTRODUCTION
• 9.2 SOLID
  • 9.2.1 ONGOING TECHNOLOGICAL INNOVATIONS TO DRIVE MARKET
• 9.3 LIQUID
  • 9.3.1 RISING APPLICATION FOR UNSTABLE DRUGS IN SOLID FORM TO BOOST DEMAND

10 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY EQUIPMENT TYPE

• 10.1 INTRODUCTION
• 10.2 PACKAGING MACHINES
  • 10.2.1 RISING NEED TO ENSURE PROTECTION AGAINST DAMAGE AND CONTAMINATION TO FUEL MARKET GROWTH
• 10.3 FILLING MACHINES
  • 10.3.1 GROWING NEED FOR COMPLIANCE WITH STRINGENT REGULATORY STANDARDS TO FOSTER MARKET GROWTH
• 10.4 SPRAY DRYING EQUIPMENT
  • 10.4.1 PRESSING NEED TO PRODUCE HIGH-QUALITY DRUG PRODUCTS TO FUEL MARKET GROWTH
• 10.5 MIXING AND BLENDING MACHINES
  • 10.5.1 ABILITY TO PROVIDE CONTROLLED AND CONSISTENT AGITATION AND SHEAR FORCES TO ENSURE HOMOGENEITY OF DRUG FORMULATION TO BOOST DEMAND
• 10.6 MILLING EQUIPMENT
  • 10.6.1 RISING NEED TO REDUCE PARTICLE SIZE OF DRUG FORMULATIONS TO FOSTER MARKET GROWTH
• 10.7 EXTRUSION EQUIPMENT
  • 10.7.1 ELEVATING USE TO PRODUCE VARIOUS DOSAGE FORMS TO FUEL MARKET GROWTH
• 10.8 TABLET COMPRESSION PRESSES
  • 10.8.1 INCREASING PREFERENCE FOR SOLID DOSAGE FORMS TO DRIVE MARKET
• 10.9 INSPECTION EQUIPMENT
  • 10.9.1 SURGING NEED TO ENSURE QUALITY AND INTEGRITY OF DRUG PRODUCTS TO FOSTER MARKET GROWTH
• 10.10 GRANULATION EQUIPMENT
  • 10.10.1 ABILITY TO IMPROVE OVERALL STABILITY AND BIOAVAILABILITY OF DRUGS TO BOOST DEMAND
• 10.11 STERILIZATION EQUIPMENT
  • 10.11.1 GROWING DEMAND FOR CONTAMINATION-FREE DRUGS AND PRODUCTS TO DRIVE MARKET

11 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Government-led initiatives to advance pharmaceutical manufacturing capacity to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Rising emphasis on strengthening domestic manufacturing capabilities to foster market growth
  • 11.2.4 MEXICO
    • 11.2.4.1 Increasing focus on streamlining pharmaceutical regulatory processes to fuel market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 UK
    • 11.3.2.1 Rising emphasis on developing advanced manufacturing equipment to offer lucrative growth opportunities
  • 11.3.3 GERMANY
    • 11.3.3.1 Escalating demand for branded and generic drugs to foster market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Government-led policies to encourage investment and innovation in pharmaceutical manufacturing industry to accelerate demand
  • 11.3.5 ITALY
    • 11.3.5.1 Growing focus on establishing pharmaceutical manufacturing facilities to create significant growth opportunities
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Surging FDIs and regulatory reforms to streamline drug approvals to offer lucrative growth opportunities
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing demand for innovative pharmaceutical manufacturing solutions to fuel market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Government-led initiatives to strengthen domestic manufacturing to boost demand
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Low import tariffs and enhanced regulatory transparency to attract foreign investments to foster market growth
  • 11.4.6 REST OF ASIA PACIFIC
• 11.5 ROW
  • 11.5.1 MACROECONOMIC OUTLOOK FOR ROW
  • 11.5.2 MIDDLE EAST
    • 11.5.2.1 Expanding pharmaceutical manufacturing infrastructure to offer growth opportunities
    • 11.5.2.2 GCC
    • 11.5.2.3 Rest of Middle East
  • 11.5.3 AFRICA
    • 11.5.3.1 Rising investment in local pharmaceutical manufacturing to fuel market growth
  • 11.5.4 SOUTH AMERICA
    • 11.5.4.1 Introduction of tax incentives to strengthen pharmaceutical manufacturing to support market growth

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2024
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS, 2024
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Primary packaging equipment footprint
    • 12.7.5.4 Secondary packaging equipment footprint
    • 12.7.5.5 Type footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 GEA GROUP AKTIENGESELLSCHAFT
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Solutions/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths/Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses/Competitive threats
  • 13.1.2 I.M.A INDUSTRIA MACCHINE AUTOMATICHE S.P.A.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Solutions/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths/Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses/Competitive threats
  • 13.1.3 SYNTEGON TECHNOLOGY GMBH
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Solutions/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths/Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses/Competitive threats
  • 13.1.4 ACG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Solutions/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
      • 13.1.4.3.2 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths/Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses/Competitive threats
  • 13.1.5 THERMO FISHER SCIENTIFIC INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Solutions/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths/Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses/Competitive threats
  • 13.1.6 ROMACO GROUP
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Solutions/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches
      • 13.1.6.3.2 Deals
  • 13.1.7 KORBER AG
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Solutions/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
      • 13.1.7.3.2 Expansions
  • 13.1.8 MARCHESINI GROUP S.P.A.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Solutions/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches
      • 13.1.8.3.2 Deals
  • 13.1.9 MG2 S.R.L.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Solutions/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
  • 13.1.10 GLATT GMBH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Solutions/Services offered
• 13.2 OTHER PLAYERS
  • 13.2.1 BAUSCH+STROBEL SE + CO. KG
  • 13.2.2 COPERION GMBH
  • 13.2.3 ELIZABETH COMPANIES
  • 13.2.4 FETTE COMPACTING
  • 13.2.5 FREUND
  • 13.2.6 KORSCH AG
  • 13.2.7 L.B. BOHLE MASCHINEN UND VERFAHREN GMBH
  • 13.2.8 LFA MACHINES
  • 13.2.9 CVC TECHNOLOGIES, INC.
  • 13.2.10 OHARA TECHNOLOGIES
  • 13.2.11 PRISM PHARMA MACHINERY
  • 13.2.12 SAINTYCO
  • 13.2.13 SILVERSON
  • 13.2.14 YENCHEN MACHINERY CO., LTD
  • 13.2.15 QUALICAPS
  • 13.2.16 COESIA S.P.A.
  • 13.2.17 UHLMANN
  • 13.2.18 AUTOMATED SYSTEMS OF TACOMA, LLC

14 APPENDIX

• 14.1 INSIGHTS FROM INDUSTRY EXPERTS
• 14.2 DISCUSSION GUIDE
• 14.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.4 CUSTOMIZATION OPTIONS
• 14.5 RELATED REPORTS
• 14.6 AUTHOR DETAILS